News and Trends 28 Jul 2022 AGC Biologics announces gene therapy partnership with Altheia Science A new development partnership between gene therapy company Altheia Sciences, which pioneers cell and gene treatments, and AGC Biologics, will look at strategies to treat autoimmune disease and cancer. Specifically, the partnership will help advance development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing. PD-L1 […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Mission Bio launches new cancer assay Life sciences company Mission Bio, Inc. has announced the availability of the industry’s first assay capable of determining measurable residual disease (MRD) in cancer down to the level of individual cells. Mission Bio said this heralds a new era for the understanding of disease progression. The single-cell multi-omics MRD (scMRD) assay for acute myeloid leukemia […] July 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDA A drug to target a rare genetic form of a neurological disease that affects the nerve cells, leading to the loss of everyday functions, could be the first of its kind available if approved. The US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) from Massachusetts-based Biogen Inc. for tofersen, an […] July 28, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Step Pharma moves into oncology clinical trials Step Pharma, which works on CTPS1 inhibition for the targeted treatment of cancer, has announced its lead asset STP938 has cleared both an Investigational New Drug (IND) application by the Food and Drug Administration (FDA), and a clinical trial application (CTA) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This means Step Pharma […] July 28, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Kelun-Biotech announces joint license agreement with MSD for drug targeting solid tumors Kelun-Biotech and MSD (Merck & Co.) have announced they are entering in a joint license agreement to develop a drug to treat solid tumors. The announcement was made yesterday (July 27) for the partnership to create the investigational antibody drug conjugate (ADC). Under the terms of the agreement, Kelun-Biotech, a clinical-stage biotech company focused on […] July 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 28 Jul 2022 How can vaccines keep up with evolving Covid-19 variants? Vaccines for COVID-19 have saved lives all over the world, but their protection is threatened by the rise of variants of concern. Companies are developing ways to combat the evolving virus, such as booster shots and universal coronavirus vaccines. During 2021, a plethora of COVID-19 vaccines was rolled out around the world. Since then, mass […] July 28, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Jul 2022 Five companies personalizing treatments with 3D printed drugs There has been a noticeable shift in recent years towards the personalization of medicine, with the pharmaceutical industry showing interest in pills that are tailored to a patient’s needs. Here are five companies that are leveraging 3D printing to produce customizable drugs. Conventional drug production relies on large-scale batch manufacturing, which is very efficient at […] July 28, 2022 - 5 minutesmins - By Omnia Ibrahim Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association Sandoz, a global pharmaceutical company working in generic and biosimilar medicines, announced this week that the US Food and Drug Administration (FDA) has accepted its biologics application (BLA) for treatment for people with multiple sclerosis (MS). The application is for a biosimilar natalizumab developed by Polpharma Biologics and includes all indications covered by the reference […] July 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2022 Commercial launch of Monkeypox PCR test announced for research A PCR test to pick up the monkeypox virus is now available outside the US for use in research applications by laboratories. Becton, Dickinson and Company (BD) a global medical technology company and CerTesy Biotec made the announcement today (July 27). The BD MAX System used to leverage the test is a fully integrated, automated […] July 28, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 AbbVie seeks nod from FDA and EMA for Crohn’s disease drug U.S. biopharma company AbbVie has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ) for the treatment of adult patients with moderately to severely active Crohn’s disease. “Crohn’s disease can be debilitating and have a significant impact on a person’s daily life,” […] July 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 T-cell therapy company AlloVir set to raise $126.6M AlloVir, Inc., a late clinical-stage allogeneic T-cell immunotherapy company, has entered into a securities purchase agreement with a group of institutional and strategic investors to sell 27,458,095 shares of common stock in a registered direct offering at a purchase price of $4.61 per share. Gross proceeds from the offering will equal approximately $126.6 million. The […] July 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jul 2022 Diffusion Pharmaceuticals to start brain tumor clinical trial U.S. biopharma company Diffusion Pharmaceuticals Inc. is set to start a new phase 2 clinical trial. Entitled “Open-Label, Dose-Escalation, Phase 2 Safety and Efficacy Study of TSC in Newly Diagnosed Glioblastoma (GBM) Patients when Administered with Standard of Care (“SOC”),” the company said the trial is a result of a collaboration with the United States […] July 27, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email